How does the Mosquirix vaccine work?
Mosquirix induces antibodies against malaria parasites that have entered the blood (via a mosquito bite) and have reached or are traveling to the liver, where they can mature and multiply. The vaccine thus limits the ability of the parasites to mature in the liver and cause clinical disease.
What kind of vaccine is Mosquirix?
GSK’s Mosquirix RTS,S/AS01e is a recombinant malaria vaccine with the P. falciparum circumsporozoite protein (CSP) from the pre-erythrocytic stage.
What is the full meaning of RTS,S?
RTS,S is a scientific name given to this malaria vaccine candidate and represents its composition. The ‘R’ stands for the central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP); the ‘T’ for the T-cell epitopes of the CSP; and the ‘S’ for hepatitis B surface antigen (HBsAg).
How is Mosquirix administered?
The vaccine is given as a 0.5 ml injection into a muscle of the thigh or in the muscle around the shoulder (the deltoid). The child is given three injections with one month between each injection. Mosquirix can only be obtained with a prescription.
How effective is Mosquirix?
Mosquirix prevents 4 in 10 cases of malaria. In terms of efficacy, we have certainly seen better, with two doses of the MMR vaccine being 97% effective against measles and 88% effective against mumps. Even the COVID-19 vaccines had higher efficacies in their clinical trials.
WHO produces Mosquirix?
The RTS,S vaccine was conceived of and created in the late 1980s by scientists working at SmithKline Beecham Biologicals (now GlaxoSmithKline (GSK) Vaccines) laboratories in Belgium….RTS,S.
| Vaccine description | |
|---|---|
| Target | P. falciparum; to a lesser extent Hepatitis B |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Mosquirix |
WHO created Mosquirix?
The vaccine was developed by GlaxoSmithKline in 1987. However, it does face challenges: Mosquirix requires up to four doses, and its protection fades after several months.
WHO invented Mosquirix?
The RTS,S vaccine, also known as Mosquirix, was developed by the British pharmaceutical company GlaxoSmithKline (GSK), and has been administered to more than 800,000 children in Ghana, Kenya and Malawi since the pilot programme began in 2019.
Who produces Mosquirix?
Who created Mosquirix?
WHO owns Mosquirix?
The vaccine recommended for use by the WHO is called Mosquirix or RTS,S. Its manufacturer, the UK pharmaceutical company GlaxoSmithKline, has been developing and testing it for more than three decades.
When was Mosquirix developed?
The vaccine was developed by GlaxoSmithKline in 1987. However, it does face challenges: Mosquirix requires up to four doses, and its protection fades after several months. Still, scientists say the vaccine could have a major impact against malaria in Africa.
Is Mosquirix FDA approved?
This parasite is mostly found in sub-Saharan Africa, but it can also be found in places like Southeast Asia and Oceania. Of note, this vaccine isn’t available in the U.S. The FDA hasn’t authorized or approved it.